Feature | Women's Health | November 11, 2015

Cutting the Cost of Breast Cancer Treatment

How two Fayetteville, Ark., medical groups found success in pioneering use of an absorbable, 3-D marker used during treatment for breast cancer

Cutting the Cost  of Breast Cancer Treatment

Breast surgeon Michael Cross, M.D., has done clinical research on the DotMed BioZorb surgical marker. (Photo courtesy of DotMed)

Breast cancer research conducted by two Fayetteville, Ark., medical groups highlights their success in pioneering use of an absorbable, three-dimensional marker used during treatment for breast cancer. Their cost analysis showed that by helping to shorten the course of radiation treatments, the surgical marker contributed to a 25 percent cost savings per patient.

Breast surgeon Michael Cross, M.D., of Breast Treatment Associates, and colleagues at Highlands Oncology Group compiled three years of data on use of the BioZorb marker from Focal Therapeutics as part of improvements in treating breast cancer. They concluded that this unique device assisted with the targeting of radiation treatments, which are usually needed after breast cancer surgery.

A Targeted Approach

The surgeon sutures the marker directly to the area that needs radiation. With the marker providing greater confidence in targeting, the doctors said they were able to use shorter courses of radiation — an approach often referred to as hypofractionated therapy.

Hypofractionated radiation treatments typically can be given over three to five weeks, compared to the usual five to seven weeks required for standard radiation therapy.

Recent studies have indicated this shorter course of treatment significantly lowers treatment costs and is just as effective in overall survival rates and preventing cancer recurrence. It also has been shown to lower toxicity and improve patients’ quality of life measures. 

Important Trends

The ability to provide radiation with equivalent success in a shorter timeframe is an important and growing trend around the world. However, adoption of these methods has previously been hindered by the difficulty in confidently defining the surgical site needing radiation.

The Fayetteville researchers’ scientific poster, which was presented at the 2015 Breast Cancer Symposium in San Francisco, summarized prospective research and clinical experience with 109 patients over three years.

BioZorb is a small coil, inserted into the breast by the surgeon at the time of tumor removal. It holds six tiny clips arranged in a three-dimensional array. This 3-D array remains over time, while the coil holding the clips dissolves.

The marker helps clinicians visualize where the tumor was removed. It can also be used to help plan and target radiation treatments done after surgery, while marking the cancer site for follow-up mammograms and other imaging studies.

“This device helps us provide shorter courses of radiation, which means less travel and time commitment for patients and is therefore much more convenient for them,” Cross said. “We are also seeing better cosmetic outcomes using this device. Because it provides a structure for the breast tissue during the healing process, it supports regrowth of healthy tissue and helps preserve the natural contour of the breast after surgery.”

Targeted Radiation

Arnold Smith, M.D., a radiation oncologist at Highlands Oncology Group who contributed to the research, said the marker “lets us clearly see where the surgeon removed the tumor, which is the spot with the greatest risk for cancer recurrence. This way, we can focus the radiation where it needs to be. That means more efficient treatment and better care for our patients.”

Scott Jones, M.S., D.A.B.R, the medical physicist at Highlands Oncology, said the device makes it easier during radiation treatment to use more sophisticated “field in field planning.” He said BioZorb also contributes to cost savings from a shorter course of radiation treatment by adding a level of confidence about the accuracy of where the radiation beam in each dose “fraction” should be aimed especially for partial breast or boost treatments.

“When you are delivering radiation with fewer fractions, you need to be sure you know exactly where the dose should be delivered, “ he said. “What BioZorb allows us to do with more confidence is to delineate the breast region more accurately within the field, to contour the dose in three dimensions and deliver each treatment very accurately.” 

Cross and his colleagues were the first in the United States to make the surgical marker available to patients. Their research on its use is the most extensive to date.

Editor’s note: More information on this research can be found at www.breasttreatment.com.

Related Content

Illinois Governor Approves State Breast Density Reporting Bill Into Law
News | Breast Density | August 13, 2018
Illinois Gov. Bruce Rauner approved the Illinois Breast Density Reporting Law (Public Act 100-0749) on Aug. 10, 2018...
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Hologic Acquires Digital Specimen Radiography Company Faxitron Bioptics

VisionCT 3-D breast specimen-designated computed tomography (CT) system. Image courtesy of Faxitron Bioptics.

News | Breast Imaging | July 31, 2018
Hologic Inc. announced it has completed the acquisition of Faxitron Bioptics, a privately-held leader in digital...
Konica Minolta Hosting Lunch and Learn at 23rd Annual Mammography Meeting in Santa Fe
News | Breast Imaging | July 31, 2018
Konica Minolta Healthcare Americas Inc. will sponsor a lunch and learn featuring its Exa Mammo platform during the 23rd...
FDA Approves New Tomosynthesis Quality Control Tests for ACR Digital Mammography QC Manual
News | Mammography | July 30, 2018
The U.S. Food and Drug Administration (FDA) recently approved the American College of Radiology’s (ACR’s) amendment to...
The Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to identify specific lymph nodes, known as sentinel lymph nodes, for surgical removal. The FDA granted approval of the Sentimag System to Endomagnetics Inc.

The  Endomagnetics' Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to identify specific lymph nodes, known as sentinel lymph nodes, for surgical removal.

Technology | Women's Health | July 24, 2018
July 24, 2018 — The U.S.
Magseed magnetic marker
Technology | Tumor Tracking Systems | July 20, 2018
Endomag, the surgical guidance company, received 510(k) clearance from the U.S.
Fujifilm to Host Pediatric Imaging Best Practices Symposium at AHRA 2018
News | Pediatric Imaging | July 18, 2018
Fujifilm Medical Systems U.S.A. Inc. announced that it will offer educational opportunities and exhibit its latest...
Overlay Init